Patents Represented by Attorney Elizabeth Dingess-Hammond

Find this attorney in the Justia Lawyer Directory

  • Crystalline compound and a process for its preparation
    Patent number: 8299059
    Abstract: A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Eli Lilly and Company
    Inventor: Christopher Luis Burcham
  • MCH receptor antagonists
    Patent number: 8263772
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: September 11, 2012
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu
  • Androgen receptor modulator and uses thereof
    Patent number: 8183388
    Abstract: The present invention relates to the compound of the formula: to pharmaceutical compositions comprising the compound of Formula (I); and to methods for treating or preventing hypogonadism, osteoporosis, osteopenia, sarcopenia, cachexia, muscle atrophy, sexual dysfunction or erectile dysfunction, comprising administering to a patient in need thereof an effective amount of the compound of Formula (I).
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: May 22, 2012
    Assignee: Eli Lilly and Company
    Inventors: Prabhakar Kondaji Jadhav, Venkatesh Krishnan
  • Compounds and methods for modulating FXR
    Patent number: 8153624
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • Compounds and methods for modulating FXR
    Patent number: 8106077
    Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: January 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M Warshawsky
  • (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis
    Patent number: 8101761
    Abstract: The present invention provides Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and discloses methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Matthew William Carson, Michael Joseph Coghlan
  • Glucocorticoid receptor modulator and methods of use
    Patent number: 8101760
    Abstract: The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Matthew William Carson, Michael Joseph Coghlan
  • MCH receptor antagonists
    Patent number: 8101764
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu, Patrick Gianpietro Spinazze
  • BACE inhibitors
    Patent number: 7648983
    Abstract: The present invention provides BACE inhibitors of Formula I: methods for their use, and intermediates and methods for their preparation.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: January 19, 2010
    Assignee: Eli Lilly and Company
    Inventors: James Edmund Audia, Dustin James Mergott, Scott Martin Sheehan, Brian Morgan Watson
  • Amides as BACE inhibitors
    Patent number: 7618978
    Abstract: The present invention provides BACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: November 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Bueno Melendo, Shu-Hui Chen, Maria Rosario Gonzalez-Garcia, James Ray McCarthy
  • Pyrrolidine derivatives useful as BACE inhibitors
    Patent number: 7585885
    Abstract: The present invention provides BACE inhibitors of Formula I: methods for their use and preparation, and intermediates for their preparation.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: September 8, 2009
    Assignee: Eli Lilly and Company
    Inventors: Timothy Alan Shepherd, Isabel Rojo Garcia